Organoids to predict treatment outcomes for breast cancer metastases
Official title: Prospective Study to Correlate the Treatment Sensitivity of Patient-derived Organoids With Clinical Outcomes in Breast Cancer Patients With Brain and/or Extra-cranial Metastases
Run by King's College London · NCT06468124 · Data updated 2026-11-12
This project will try to grow mini-tumors (organoids) from people with breast cancer metastases to see if lab responses predict each patient’s response to radiation and chemotherapy.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | King's College London Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 2 sites (London and 1 other locations) |
| Status | Recruiting |
| Started | May 27, 2025 |
| Main results expected | June 30, 2026 |
| Study ends | June 30, 2026 |
| Registry record updated | December 22, 2025 |
| Trial ID | NCT06468124 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (age >18) with breast cancer who are undergoing surgical resection or biopsy of brain or extra‑cranial metastases and who can give informed consent are ideal candidates.
✕Probably not a fit
Patients without resectable or biopsiable metastatic tissue, those unable to consent, or those whose tumor samples fail to grow organoids are unlikely to benefit directly.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The project will collect tissue from surgically resected or biopsied brain and extra‑cranial breast cancer metastases and generate patient‑derived organoids (PDOs). When organoids contain sufficient cells, investigators will expose them to increasing doses of radiotherapy and to the systemic treatments the patients received or will receive to measure dose‑response and IC50. Researchers will correlate PDO radio‑ and chemo‑sensitivity with patients’ clinical treatment responses and survival while patients continue standard clinical care. The pilot phase aims to enroll about 20 patients at two London hospital sites.
Why it matters
Potential benefit: If successful, PDO testing could help personalize therapy by identifying which radiation or systemic treatments are most likely to work for an individual patient's metastases.
How similar studies have gone: Organoid-based drug testing has shown promising concordance with patient response in several cancer types and small breast cancer series, but its use to predict outcomes for metastatic breast cancer remains experimental.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Breast cancer patients with brain metastases who are suitable for surgical resection or Breast cancer patients with extra-cranial metastases undergoing surgical resection or biopsy * Age \> 18 years old Exclusion Criteria: * Patients unable to give informed consent e.g., mental disability or vulnerable adults
Where it's running
-
Guy's and St. Thomas NHS Foundation Trust
London, United Kingdom Recruiting -
King's College Hospital NHS Foundation Trust
London, United Kingdom Recruiting
Study contacts
- Principal investigator: Anthony Kong — Clinical reader and honorary NHS consultant in clinical oncology
- Study coordinator: Anthony Kong
- Email: Anthony.kong@kcl.ac.uk
- Phone: 0207 848 8302
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Improved Facial Skin Quality After VYC-12L for Breast Cancer Survivors
This study tests whether intradermal injections of VYC-12L can improve facial skin quality and quality of life in adults who have completed breast cancer treatment.
-
Breast cancer subtypes and outcomes in Colombian women
This study looks back at medical records of women with breast cancer to see how different molecular subtypes relate to survival and recurrence in a single Colombian hospital.
-
Multimodal psychosomatic symptom care for breast cancer: personalized acupuncture care guided by shared decision-making
This study tests whether personalized acupuncture options (manual acupuncture, ear acupuncture, or both) can help women with breast cancer who have anxiety, sleep problems, or fatigue, compared to routine nursing care.
-
Slow Jogging for Breast Cancer Survivors
This study tests whether a 12-week slow jogging program helps sleep quality in women who have completed breast cancer treatment.
-
Methylscape test in body fluids for multi-cancer detection in Colombia
A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.
-
Benchmarking AI language models against tumor boards for oncology treatment decisions
This project tests whether frontier AI language models can match the treatment recommendations of multidisciplinary tumor boards for common cancers using standardized synthetic cases.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.